[Drug therapy of tachyarrhythmias (author's transl)].
D000200:Action Potentials / Q000187:drug effects; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000404:Ajmaline / Q000627:therapeutic use; D000638:Amiodarone / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001073:Aprindine / Q000627:therapeutic use; D002118:Calcium / Q000037:antagonists & inhibitors; D004206:Disopyramide / Q000627:therapeutic use; D004594:Electrophysiology; D006801:Humans; D008012:Lidocaine / Q000627:therapeutic use; D008801:Mexiletine / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy; D010672:Phenytoin / Q000627:therapeutic use; D011342:Procainamide / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use; D013610:Tachycardia / Q000188:drug therapy*; D014700:Verapamil / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D000404:Ajmaline; D008801:Mexiletine; D001073:Aprindine; D010672:Phenytoin; D008012:Lidocaine; D014700:Verapamil; D004206:Disopyramide; D011802:Quinidine; D011342:Procainamide; D000638:Amiodarone; D002118:Calcium
Medikamentöse Therapie tachykarder Herzrhythmusstörungen.